Trial Profile
A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bellicum Pharmaceuticals
- 10 Jul 2022 Planned End Date changed from 1 Jul 2035 to 1 Sep 2035.
- 10 Jul 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Sep 2022.
- 01 Oct 2020 Planned End Date changed from 1 Mar 2035 to 1 Jul 2035.